Painless TrkA-NAM
Severe Pain (e.g., Osteoarthritis)
Pre-clinicalActive
Key Facts
About AlzeCure Pharma
AlzeCure Pharma is a clinical-stage biotech company developing novel therapies for Alzheimer's disease, cognitive disorders, and neuropathic pain through its three proprietary platforms: NeuroRestore (symptomatic), Alzstatin (disease-modifying), and Painless. Its lead asset, NeuroRestore ACD856, is being prepared for a Phase 2a trial in Alzheimer's with support from a EUR 2.5 million EU grant. The company is publicly listed on Nasdaq First North Premier Growth Market and follows a business model of internal R&D through early clinical phases followed by out-licensing.
View full company profile